2. Smithsonian Libraries. Systema Naturae. Available at https://library.si.edu/donate/adopt-a-book/systema-naturae-quo-proponuntur-naturae-regna-tria-secundum-classes-ordines. Last accessed April 22, 2026.
3. Berger D. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 1: ancient times through the 19th century. MLO Med Lab Obs. 1999;31(7):28-30, 32, 34-40.
4. RxList. Definition of Koch's Postulates. Available at https://www.rxlist.com/kochs_postulates/definition.htm. Last accessed April 22, 2026.
5. Berger D. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 2: laboratory science and professional certification in the 20th century. MLO Med Lab Obs. 1999;31(8):32-34, 36, 38.
6. Centers for Disease Control and Prevention. Eastern equine encephalitis—Florida, eastern United States, 1991. MMWR. 1991;40(31):533-535.
7. Burroughs T, Knobler S, Lederberg J (eds). The Emergence of Zoonotic Diseases: Understanding the Impact on Animal and Human Health. Washington, DC: National Academy Press; 2002.
8. Gilbert AT, Petersen BW, Recuenco S, et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. Am J Trop Med Hyg. 2012;87(2):206-215.
9. Sanchez A, Ksiazek TG, Rollin PE, et al. Reemergence of Ebola virus in Africa. Emerg Infect Dis. 1995;1(3):96-97.
10. Centers for Disease Control and Prevention. About Parasites. Available at https://www.cdc.gov/parasites/about. Last accessed April 22, 2026.
11. Horton HH, Misrahi JJ, Matthews GW, Kocher PL. Critical biological agents: disease reporting as a tool for determining bioterrorism preparedness. J Law Med Ethics. 2002;30(2):262-266.
12. Heymann DL (ed). Control of Communicable Diseases Manual. 21st ed. Washington, DC: World Health Organization/American Public Health Association; 2022.
13. Centers for Disease Control and Prevention. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern: Taeniasis. Available at https://www.cdc.gov/dpdx/taeniasis/index.html. Last accessed April 22, 2026.
14. Hugh-Jones ME, Hubbert WT, Hagstad HV. Zoonoses: Recognition, Control and Prevention. Ames, IA: University of Iowa Press; 1995.
15. Huff JL, Eberle R, Capitanio J, Zhou SS, Barry PA. Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol. 2003;84(Pt 1):83-92.
16. National Institute of Allergy and Infectious Diseases. Lyme Disease. Available at https://www.niaid.nih.gov/diseases-conditions/lyme-disease. Last accessed April 22, 2026.
17. Schwartz AM, Hinckley AF, Mead PS, et al. Surveillance for Lyme disease – United States, 2008-2015. MMWR. 2017;66(22):1-12.
18. Centers for Disease Control and Prevention. Lyme Disease Surveillance and Data. Available at https://www.cdc.gov/lyme/data-research/facts-stats/index.html. Last accessed April 22, 2026.
19. Association of Public Health Laboratories. Suggested Reporting Language, Interpretation and Guidance Regarding Lyme Disease Serologic Test Results. Available at https://www.aphl.org/aboutAPHL/publications/Documents/ID-2024-Lyme-Disease-Serologic-Testing-Reporting.pdf. Last accessed April 22, 2026.
20. Grier T. Will There Ever Be an Accurate Test for Lyme Disease? Available at https://owndoc.com/pdf/when-accurate-lyme-tests.pdf. Last accessed April 22, 2026.
21. Lin T, Oliver JH Jr, Gao L, Kollars TM Jr, Clark KL. Genetic heterogeneity of Borrelia burgdorferi sensu lato in the southern United States based on restriction fragment length polymorphism and sequence analysis. J Clin Microbiol. 2001;39(7):2500-2507.
22. Centers for Disease Control and Prevention. [Archived Content]. New Lyme-Disease-Causing Bacteria Species Discovered. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/media/releases/2016/p0208-lyme-disease.html. Last accessed April 22, 2026.
23. Salkeld DJ, Leonhard S, Girard YA, et al. Identifying the reservoir hosts of the Lyme disease spirochete Borrelia burgdorferi in California: the role of the western gray squirrel (Sciurus griseus). Am J Trop Med Hyg. 2008;79(4):535-540.
25. Steere AC. A 58-year old man with a diagnosis of chronic Lyme disease. JAMA. 2002;288(8):1002-1010.
26. Spielman A. Host Abundance and Transmission of Ixodes-Borne Zoonoses. Cambridge, MA: Harvard University Press; 1994.
27. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004;113(8):1093-1101.
28. Depietropaolo DL, Powers JH, Gill JM. Diagnosis of Lyme disease. Am Fam Physician. 2005;72(2):297-304.
29. Steere AC, McHugh G, Suarez C, Hoitt J, Damle N, Sikland VK. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis. 2003;36(8):1078-1081.
30. Centers for Disease Control and Prevention. About Ehrlichiosis. Available at https://www.cdc.gov/ehrlichiosis/about/index.html. Last accessed April 22, 2026.
31. Telford SR 3rd, Pollack RJ, Spielman A. Emerging vector-borne infections. Infect Dis Clin North Am. 1991;5(1):7-17.
32. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med. 1988;319(22):1441-1446.
33. Centers for Disease Control and Prevention. Clinical Testing and Diagnosis for Lyme Disease. Available at https://www.cdc.gov/lyme/hcp/diagnosis-testing. Last accessed April 22, 2026.
34. Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR. 2019;68(32):703.
35. U.S. Food and Drug Administration. FDA News Release: FDA Clears New Indications for Existing Lyme Disease Tests That May Help Streamline Diagnoses. Available at https://www.fda.gov/news-events/press-announcements/fda-clears-new-indications-existing-lyme-disease-tests-may-help-streamline-diagnoses. Last accessed April 22, 2026.
36. Centers for Disease Control and Prevention. Infectious Diseases Laboratories: Test Directory. Available at https://www.cdc.gov/infectious-diseases-labs/php/test-directory/index.html. Last accessed April 22, 2026.
38. Centers for Disease Control and Prevention. Notice to readers: recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR. 1995;44(31):590-591.
39. Centers for Disease Control and Prevention. Notice to readers: caution regarding testing for Lyme disease. MMWR. 2005;54(5):125.
40. Meyerhoff JO. Lyme Disease. Available at https://emedicine.medscape.com/article/330178-overview. Last accessed April 22, 2026.
41. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135.
42. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Neurology. 2021;96(6):262-273.
43. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134.
44. Centers for Disease Control and Prevention. West Nile Virus. Available at https://www.cdc.gov/west-nile-virus/. Last accessed April 22, 2026.
45. Centers for Disease Control and Prevention. Lyme Disease Vaccine. Available at https://www.cdc.gov/lyme/about/lyme-disease-vaccine.html. Last accessed April 22, 2026.
46. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.
47. Centers for Disease Control and Prevention. About Tularemia. Available at https://www.cdc.gov/tularemia/about/. Last accessed April 22, 2026.
49. Cleveland KO. Tularemia. Available at https://emedicine.medscape.com/article/230923-overview. Last accessed April 22, 2026.
50. Merck Manual. Tularemia. Available at https://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/tularemia. Last accessed April 22, 2026.
51. New York State Department of Health. Tularemia. Available at https://www.health.ny.gov/diseases/communicable/tularemia/fact_sheet.htm. Last accessed April 22, 2026.
52. Centers for Disease Control and Prevention. Tularemia associated with a hamster bite—Colorado, 2004. MMWR. 2005;53(51):1202-1203.
53. Yuen JC, Malotky MV. Francisella tularensis osteomyelitis of the hand following a cat bite: a case of clinical suspicion. Plast Reconstr Surg. 2011;128(1):37e-39e.
55. LexiDrug. Available at https://online.lexi.com. Last accessed April 22, 2026.
56. Reed DS, Smith LP, Cole KS, Santiago AE, Mann BJ, Barry EM. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Am Soc Microbiol. 2014;82(5):2098-2105.
57. Centers for Disease Control and Prevention. Preventing Tularemia. Available at https://www.cdc.gov/tularemia/prevention. Last accessed April 22, 2026.
58. Centers for Disease Control and Prevention. About Rocky Mountain Spotted Fever. Available at https://www.cdc.gov/rocky-mountain-spotted-fever/about/index.html. Last accessed April 22, 2026.
59. Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med. 2005;353(6):587-594.
60. Rasmussen SA, Kent CK, Casey CG, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States. MMWR;65(2):1-44.
61. Pritt BS, Sloan LM, Hoang DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med. 2011;365(5):422-429.
62. New York State Department of Health. Anaplasmosis and Ehrlichiosis: Tick-Borne Bacterial Infections. Available at https://www.health.ny.gov/diseases/communicable/ehrlichiosis/fact_sheet.htm. Last accessed April 22, 2026.
63. Centers for Disease Control and Prevention. Clinical Overview of Ehrlichiosis. Available at https://www.cdc.gov/ehrlichiosis/hcp/clinical-overview/index.html. Last accessed April 22, 2026.
64. Romer Y, Adcock K, Wei Z, et al. Isolation of Heartland virus from lone star ticks, Georgia, USA, 2019. Emerg Infect Dis. 2022;28(4):786-792.
65. Pastula DM, Turabelidze G, Yates KF. Notes from the field: Heartland virus disease—United States, 2012–2013. MMWR. 2014;63(12):270-271.
66. Centers for Disease Control and Prevention. Clinical Overview of Babesiosis. Available at https://www.cdc.gov/babesiosis/hcp/clinical-overview/index.html.ast accessed April 22, 2026.
67. Western KA, Benson GD, Gleason NN, Healy GR, Schultz MG. Babesiosis in a Massachusetts resident. N Engl J Med. 1970;283(16): 854-856.
68. Centers for Disease Control and Prevention. Yellow Book. Available at https://www.cdc.gov/yellow-book/index.html. Last accessed April 22, 2026.
70. Centers for Disease Control and Prevention. Data and Maps for West Nile. Available at https://www.cdc.gov/west-nile-virus/data-maps. Last accessed April 22, 2026.
71. Government of Canada. Surveillance of West Nile Virus. Available at https://www.canada.ca/en/public-health/services/diseases/west-nile-virus/surveillance-west-nile-virus.html. Last accessed April 22, 2026.
72. Scherret JH, Poidinger M, Mackenzie JS, et al. The relationships between West Nile and Kunjin viruses. Emerg Infect Dis. 2001;7(4):697-705.
73. Centers for Disease Control and Prevention. West Nile virus activity: Eastern United States, 2001. MMWR. 2001;50(29):617-619.
74. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis. 2002;2(9):519-529.
75. Klenk K, Snow J, Morgan K, et al. Alligators as West Nile virus amplifiers. Emerg Infect Dis. 2004;10(12):2150-2155.
76. Centers for Disease Control and Prevention. Update: West Nile virus activity—Northeastern United States, 2000. MMWR. 2000;49(36):820-822.
77. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137(3):173-179.
78. Centers for Disease Control and Prevention. Clinical Signs and Symptoms of West Nile Virus Disease. Available at https://www.cdc.gov/west-nile-virus/hcp/clinical-signs/index.html#. Last accessed April 22, 2026.
79. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4): 511-515.
80. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174-1179.
81. Centers for Disease Control and Prevention. Guidelines for West Nile Virus Surveillance and Control. Available at https://www.cdc.gov/west-nile-virus/php/surveillance-and-control-guidelines/index.html. Last accessed April 22, 2026.
82. Salinas JD Jr. West Nile Virus. Available at https://emedicine.medscape.com/article/312210-overview. Last accessed April 22, 2026.
83. Centers for Disease Control and Prevention. West Nile Virus. Clinical Treatment and Prevention. Available at https://www.cdc.gov/west-nile-virus/hcp/treatment-prevention/index.html. Last accessed April 22, 2026.
84. Fierce Pharma. NIH-Funded Vaccine for West Nile Virus Enters Human Clinical Trials. Available at https://www.fiercepharma.com/vaccines/nih-funded-vaccine-for-west-nile-virus-enters-human-clinical-trials. Last accessed April 22, 2026.
85. ClinicalTrials.gov. Phase 1 Trial of Inactivated West Nile Virus Vaccine. Available at https://clinicaltrials.gov/ct2/show/NCT02337868. Last accessed April 22, 2026.
87. Fauci AS, Morens DM. Zika virus in the Americas: yet another arbovirus threat. N Engl J Med. 2016;374(7):601-604.
88. Centers for Disease Control and Prevention. Zika Cases in the United States. Available at https://www.cdc.gov/zika/zika-cases-us. Last accessed April 22, 2026.
89. Monaghan AJ, Morin CW, Steinhoff DF, et al. On the seasonal occurrence and abundance of the Zika virus vector mosquito Aedes aegypti in the contiguous United States. PLoS Curr. 2016;1.
90. Hills SL, Russell K, Hennessey M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—continental United States, 2016. MMWR. 2016;65(8):215-216.
91. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Zika Virus Epidemic: Potential Association with Microcephaly and Guillain-Barré Syndrome, Second Update. Available at https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-zika-virus-disease-epidemic-potential-association-0. Last accessed April 22, 2026.
92. U.S. Food and Drug Administration. FDA Advises Testing for Zika Virus in All Donated Blood and Blood Components in the US. Available at https://www.fda.gov/news-events/press-announcements/fda-advises-testing-zika-virus-all-donated-blood-and-blood-components-us. Last accessed April 22, 2026.
93. Centers for Disease Control and Prevention. Zika and Blood and Tissue Safety. Available at https://www.cdc.gov/zika/blood-tissue-safety/index.html. Last accessed April 22, 2026.
94. Oster AM, Russell K, Stryker JE, et al. Update: interim guidance for prevention of sexual transmission of Zika virus—United States, 2016. MMWR. 2016;65(12):323-325.
95. Polen KD, Gilboa SM, Hills S, et al. Update: Interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for men with possible Zika virus exposure—United States, August 2018. MMWR. 2018;67(31):868-871.
97. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016;374(16):1552-1563.
98. Brasil P, Pereira JP Jr, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro: preliminary report. Obstet Gynecol Surv. 2016;71(6):331-333.
99. Carteaux G, Maquart M, Bedet A, et al. Zika virus associated with meningoencephalitis. N Engl J Med. 2016;374(16):1595-1596.
100. Karimi O, Goorhuis A, Schinkel J, et al. Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. Lancet. 2016;387(10022):939-940.
101. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas: region of the Americas, May 2015–January 2016. MMWR. 2016;65(3):55-58.
102. Centers for Disease Control and Prevention. Clinical Testing and Diagnosis for Zika Virus Disease. Available at https://www.cdc.gov/zika/hcp/diagnosis-testing. Last accessed April 22, 2026.
103. U.S. Food and Drug Administration. Emergency Use Authorizations for Medical Devices. Zika Virus Emergency Use Authorization. Available at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations-medical-devices#zika. Last accessed April 22, 2026.
104. Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR. 2016;65(21): 543-546.
105. Oduyebo T, Igbinosa I, Petersen EE, et al. Update: interim guidance for health care providers caring for pregnant women with possible Zika virus exposure—United States (Including U.S. Territories), July 2017. MMWR. 2017;66(29):781-793.
106. World Health Organization. Dengue. Available at https://www.who.int/en/news-room/fact-sheets/detail/dengue-and-severe-dengue. Last accessed April 22, 2026.
107. Centers for Disease Control and Prevention. About Dengue. Available at https://www.cdc.gov/dengue/about/index.html. Last accessed April 22, 2026.
108. Centers for Disease Control and Prevention. Data and Statistics on Dengue in the United States. Available at https://www.cdc.gov/dengue/data-research/facts-stats/index.html. Last accessed April 22, 2026.
109. Centers for Disease Control and Prevention. Dengue. Available at https://www.cdc.gov/dengue. Last accessed April 22, 2026.
110. Centers for Disease Control and Prevention. Dengue For Health Care Providers. Available at https://www.cdc.gov/dengue/site.html#hcp. Last accessed April 22, 2026.
111. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Dengue and Dengue Hemorrhagic Fever: Information for Health Care Practitioners. Available at https://stacks.cdc.gov/view/cdc/11539. Last accessed April 22, 2026.
112. U.S. Food and Drug Administration. BLA Approval. Available at https://www.fda.gov/media/124402/download. Last accessed April 22, 2026.
113. Kirkpatrick BD, Whitehead SS, Pierce KK. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in human challenge model. Sci Transl Med. 2016;8(330):330.
114. U.S. National Library of medicine. ClinicalTrials.gov. Available at https://clinicaltrials.gov/search?cond=Dengue&viewType=Table. Last accessed April 22, 2026.
115. Zandi F, Goshadrou F, Meyfour A, Vaziri B. Rabies infection: an overview of Lyssavirus-host protein interactions. Iran Biomed J. 2021;25(4):226-242.
116. Centers for Disease Control and Prevention. Rabies in the United States: Protecting Public Health. Available at https://www.cdc.gov/rabies/php/protecting-public-health. Last accessed April 22, 2026.
117. Monroe BP, Yager P, Blanton J, et al. Rabies surveillance in the United States during 2014. J Am Vet Med Assoc. 2016;248(7):777-788.
118. World Health Organization. Rabies. Available at https://www.who.int/health-topics/rabies#tab=tab_1. Last accessed April 22, 2026.
119. Ma X, Bonaparte S, Corbett P, et al. Rabies surveillance in the United States during 2021. J Am Vet Med Assoc. 2023;261(7):1045-1053.
120. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352(11):1103-1111.
121. Boutelle C, Bonaparte S, Orciari LA, et al. Rabies surveillance in the United States during 2023. JAVMA. 2025;263(10):1310-1317.
122. Wilde H, Briggs DJ, Meslin FX, Hemachttdha T, Sitprija V. Rabies update for travel medicine advisors. Clin Infect Dis. 2003;37(1):96-100.
123. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60-63.
124. Centers for Disease Control and Prevention. Clinical Overview of Rabies Available at https://www.cdc.gov/rabies/hcp/clinical-overview. Last accessed April 22, 2026.
125. Centers for Disease Control and Prevention. Human rabies prevention—United States, 2008. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR03):1-26, 28.
126. Centers for Disease Control and Prevention. Human death associated with bat rabies—California, 2003. MMWR. 2004;53(2):33-35.
127. Centers for Disease Control and Prevention. Laboratory Methods for Rabies Testing. Available at https://www.cdc.gov/rabies/php/labs-specimens/testing.html. Last accessed April 22, 2026.
128. Centers for Disease Control and Prevention. Rabies Vaccine VIS. Available at https://www.cdc.gov/vaccines/hcp/current-vis/rabies.html. Last accessed April 22, 2026.
129. World Health Organization. WHO Guide for Rabies Pre- and Post-Exposure Prophylaxis in Humans. Updated 2014. Available at https://cdn.who.int/media/docs/default-source/searo/india/health-topic-pdf/pep-prophylaxis-guideline-15-12-2014.pdf?sfvrsn=8619bec3_2.Last accessed April 22, 2026.
130. Rao AK, Briggs D, Moore SM, et al. Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR. 2022;71(18):619-627.
131. Medical College of Wisconsin. Pediatric Infectious Diseases. Welcome to the Rabies Registry Website. Available at https://www.mcw.edu/departments/pediatrics/divisions/infectious-diseases/rabies-registry-website. Last accessed April 22, 2026.
132. Centers for Disease Control and Prevention. Recovery of a patient from clinical rabies—Wisconsin, 2004. MMWR. 2004;53(50):1171-1173.
133. Centers for Disease Control and Prevention. Compendium of animal rabies prevention and control, 2005. MMWR. 2005;54(RR03): 1-8.
134. Centers for Disease Control and Prevention. Rabies Pre-Exposure Prophylaxis Guidance. Available at https://www.cdc.gov/rabies/hcp/clinical-care/pre-exposure-prophylaxis.html. Last accessed April 22, 2026.
135. World Health Organization. Rabies Vaccines: WHO Position Paper—April 2018. Available at https://www.who.int/publications/i/item/who-wer9316. Last accessed April 22, 2026.
136. Olsen CW. Influenza: pigs, people and public health. National Pork Board: Public Health Fact Sheet. 2004;2(6):1-3.
137. Centers for Disease Control and Prevention. Bird Flu: Causes and How it Spreads. Available at https://www.cdc.gov/bird-flu/virus-transmission/. Last accessed April 22, 2026.
138. World Health Organization. Cumulative Number of Confirmed Human Cases for Avian Influenza A(H5N1) Reported to WHO, 2003–2023. Available at https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2022-5-jan-2023. Last accessed April 22, 2026.
139. Centers for Disease Control and Prevention. First Human Avian Influenza A (H5N1) Virus Infection Reported in Americas. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/flu/news/first-human-h5n1-americas.htm. Last accessed April 22, 2026.
140. World Health Organization. Avian Influenza: Assessing the Pandemic Threat. Available at https://iris.who.int/server/api/core/bitstreams/62125dd4-b5fa-4bd3-b357-908fe4087660/content. Last accessed April 22, 2026.
141. Centers for Disease Control and Prevention. Archived: Public Health Threat of Highly Pathogenic Asian Avian Influenza A (H5N1) Virus. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/flu/avianflu/h5n1-threat.htm. Last accessed April 22, 2026.
142. World Health Organization. Avian Influenza: 2006—Indonesia. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2006_05_22-en. Last accessed April 22, 2026.
143. Centers for Disease Control and Prevention. Avian Influenza Type A. Available at https://www.cdc.gov/bird-flu/about/avian-influenza-type-a.html. Last accessed April 22, 2026.
144. Hitt E. Avian Flu: What Clinicians Need to Know. Available at https://www.medscape.com/viewarticle/468007. Last accessed April 22, 2026.
145. U.S. Department of Agriculture. USDA Avian Influenza Face Sheet. Available athttps://www.usda.gov/sites/default/files/documents/usda-avian-influenza-factsheet.pdf. Last accessed April 22, 2026.
146. World Health Organization. Influenza (Avian and Other Zoonotic). Available at https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic). Last accessed April 22, 2026.
147. Li C, Hatta M, Nidom CA, et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci U S A. 2010;107(10):4687-4692.
148. World Health Organization. Influenza A(H5N1) Highly Pathogenic Avian Influenza: Timeline of Major Events. Available at https://www.who.int/publications/m/item/influenza-a(h5n1)-highly-pathogenic-avian-influenza-timeline-of-major-events. Last accessed April 22, 2026.
149. Centers for Disease Control and Prevention. A(H5) Bird Flu: Current Situation. Available at https://www.cdc.gov/bird-flu/situation-summary/index.html? Last accessed April 22, 2026.
150. Centers for Disease Control and Prevention. Reported Human Infections with Avian Influenza A Viruses. Available at https://www.cdc.gov/bird-flu/php/surveillance/reported-human-infections.html. Last accessed April 22, 2026.
151. Centers for Disease Control and Prevention. Treatment of Bird Flu. Available at https://www.cdc.gov/bird-flu/treatment/index.html. Last accessed April 22, 2026.
152. Centers for Disease Control and Prevention. Emergency Use Instructions for Oseltamivir. Available at https://www.cdc.gov/bird-flu/hcp/emergency-use-oseltamivir/index.html. Last accessed April 22, 2026.
153. Kayali G, Kandeil A, El-Shesheny R, et al. Avian influenza A(H5N1) virus in Egypt. Emerg Infect Dis. 2016;22(3).
154. Crispin SW, Cohen M, Mapes T. Bird-flu outbreak revives concerns stirred by SARS. Wall St J. January 28, 2004:A1.
155. Infection Control. NIH Scientists Target Future Pandemic Strains of H5N1 Avian Influenza. Available at https://www.infectioncontroltoday.com/view/nih-scientists-target-future-pandemic-strains-h5n1-avian-influenza. Last accessed April 22, 2026.
156. Gamblin SJ, Haire LF, Russell RJ, et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science. 2004;303(5665):1838-1842.
157. Centers for Disease Control and Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone high-dose) and guidance for use—United States, 2010. MMWR. 2010;59(16):485-486.
158. Centers for Disease Control and Prevention. [Archived Content]. Bird Infections with Highly-Pathogenic Avian Influenza A (H5N2), (H5N8), and (H5N1) Viruses: Recommendations for Human Health Investigations and Response. Available at https://stacks.cdc.gov/view/cdc/31362. Last accessed April 22, 2026.
159. Centers for Disease Control and Prevention. Avian Influenza (Bird Flu). Available at https://www.cdc.gov/bird-flu/index.html. Last accessed April 22, 2026.
160. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004;363(9409):587-593.
161. World Health Organization. WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus. Available at https://iris.who.int/server/api/core/bitstreams/3551886c-7d08-43e4-a21a-c5c1d9573086/content. Last accessed April 22, 2026.
162. Centers for Disease Control and Prevention. Avian Influenza (Bird Flu). Available at https://www.cdc.gov/bird-flu/. Last accessed April 22, 2026.
163. Centers for Disease Control and Prevention. [Archived Content]. Interim Guidance for Airline Flight Crews and Persons Meeting Passengers Arriving from Areas with Avian Influenza (Updated). Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/h1n1flu/guidance/air-crew-dom-intl.htm. Last accessed April 22, 2026.
164. World Health Organization. Global Influenza Programme. Zoonotic Influenza Candidate Vaccine Viruses and Potency Testing Reagents. Available at https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses. Last accessed April 22, 2026.
165. GlaxoKlineSmith. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen; First Clinical Trials of Candidate Pre-Pandemic Flu Vaccine to Start. Available at https://www.infectioncontroltoday.com/guidelines/glaxosmithkline-receives-new-hhs-order-h5n1-bulk-antigen-first-clinical-trials-candidate. Last accessed April 22, 2026.
166. Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26(3):476-492.
167. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting: Highly Pathogenic Avian Influenza (H5) Virus Vaccines. Available at https://www.fda.gov/media/182543/download. Last accessed April 22, 2026.
168. U.S. Food and Drug Administration. Influenza Virus Vaccine, H5N1 (for National Stockpile). Available at https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/influenza-virus-vaccine-h5n1-national-stockpile. Last accessed April 2, 2026.
169. Science Daily. Universal Influenza Vaccine Tested Successfully in Humans. Available at https://www.sciencedaily.com/releases/2008/01/080124185522.htm. Last accessed April 22, 2026.
170. World Health Organization. Zoonotic Influenza Candidate Vaccine Viruses and Potency Testing Reagents. Influenza A (H5N1). Summary of Status of Development and Available of A(H5N1) Candidate Vaccine Viruses and Potency Testing Reagents. Available at https://cdn.who.int/media/docs/default-source/cvv-zoonotic-northern-hemisphere-2026-2027/1.-a(h5n1).pdf?sfvrsn=e33fbedb_6. Last accessed April 22, 2026.
171. The IVR Initiative: Influenza Vaccines Roadmap. Available at https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape. Last accessed April 22, 2026.
172. Centers for Disease Control and Prevention. About Swine/Variant Flu. Available at https://www.cdc.gov/swine-flu/about/index.html. Last accessed April 22, 2026.
173. World Health Organization. Avian Influenza Update: Implications of H5N1 Infections in Pigs in China. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2004_08_25-en. Last accessed April 22, 2026.
174. World Health Organization. Pandemic (H1N1) 2010. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2010_07_30-en. Last accessed April 22, 2026.
175. Centers for Disease Control and Prevention. [Archived Content]. 2009 H1N1 Flu/H1N1 Flu and You. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/h1n1flu/qa.htm. Last accessed April 22, 2026.
176. Centers for Disease Control and Prevention. [Archived Content]. CDC H1N1 Flu: Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009–2010 Season. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/h1n1flu/recommendations.htm. Last accessed April 22, 2026.
177. World Health Organization. H1N1 in Post-Pandemic Period. Available at https://www.who.int/news/item/10-08-2010-h1n1-in-post-pandemic-period. Last accessed April 22, 2026.
178. Centers for Disease Control and Prevention. [Archived Content]. 2009 H1N1 Pandemic Timeline. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/flu/pandemic-resources/2009-pandemic-timeline.html. Last accessed April 22, 2026.
179. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2025–26 influenza season. MMWR. 2025;74(32):500-507.
180. Centers for Disease Control and Prevention. [Archived Content]. Interim Guidance on Infection Control Measures for 2009 H1N1 Influenza in Healthcare Settings, Including Protection of Healthcare Personnel. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/h1n1flu/guidelines_infection_control.htm. Last accessed April 22, 2026.
181. California Department of Public Health. CDPH Variant (Swine) Influenza Quicksheet. Available at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Respiratory-Viruses/VariantInfluenzaGuidance.aspx. Last accessed April 22, 2026.
182. Lau JTF, Griffiths S, Choi K-C, Lin C. Prevalence of preventive behaviors and associated factors during early phase of the H1N1 influenza epidemic. Am J Infect Control. 2010;38(5):374-380.
183. Fiore AE, Uyeki TM, Broder KM, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59(RR8):1-62.
184. Centers for Disease Control and Prevention. Interim Guidance for Clinicians on Human Infections with Variant Influenza Viruses. Available at https://www.cdc.gov/swine-flu/php/guidance/human-infections-variant-influenza-viruses.html. Last accessed April 22, 2026.
185. Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2009;58(RR10):1-8.
186. Centers for Disease Control and Prevention. ACIP Recommendations Summary. Available at https://www.cdc.gov/flu/hcp/acip. Last accessed April 22, 2026.
187. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2008;57(RR7):1-60.
188. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. Available at https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html. Last accessed April 22, 2026.
189. U.S. Food and Drug Administration. BAT (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) (Equine). Available at https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/bat-botulism-antitoxin-heptavalent-b-c-d-e-f-g-equine. Last accessed April 22, 2026.
190. Centers for Disease Control and Prevention. Antiviral Drug Resistance among Influenza Viruses. Available at https://www.cdc.gov/flu/hcp/antivirals/antiviral-drug-resistance.html. Last accessed April 22, 2026.
191. Koszalka P, Subbarao K, Baz M. Preclinical and clinical developments for combination treatment of influenza. PlOS Pathogens. 2022;18(5):e1010481.
192. Centers for Disease Control and Prevention. Reported Cases of Hantavirus Disease. Available at https://www.cdc.gov/hantavirus/data-research/cases. Last accessed April 22, 2026.
193. Centers for Disease Control and Prevention. About Hantavirus. Available at https://www.cdc.gov/hantavirus/about/index.html. Last accessed April 22, 2026.
194. Fill MA, Mullins H, May AS, et al. Notes from the field: multiple cases of Seoul virus infection in a household with infected pet rats - Tennessee, December 2016-April 2017. MMWR. 2017;66(40):1081-1082.
195. Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome—Vermont, 2000. MMWR. 2001;50(28):603-605.
196. Black WC 4th, Doty JB, Hughes MT, Beaty BJ, Calisher CH. Temporal and geographic evidence for evolution of Sin Nombre virus using molecular analyses of viral RNA from Colorado, New Mexico and Montana. Virol J. 2009;6:102.
197. Centers for Disease Control and Prevention. Clinician Brief: Hantavirus Pulmonary Syndrome. Available at https://www.cdc.gov/hantavirus/hcp/clinical-overview/hps.html. Last accessed April 22, 2026.
198. American Lung Association. Hantavirus Pulmonary Syndrome: Symptoms and Diagnosis. Available at https://www.lung.org/lung-health-diseases/lung-disease-lookup/hantavirus-pulmonary-syndrome/symptoms-diagnosis. Last accessed April 22, 2026.
199. Centers for Disease Control and Prevention. How to Clean Up After Rodents. Available at https://www.cdc.gov/healthy-pets/rodent-control/clean-up.html. Last accessed April 22, 2026.
200. Centers for Disease Control and Prevention. About Lymphocytic Choriomeningitis. Available at https://www.cdc.gov/lymphocytic-choriomeningitis/about/index.html. Last accessed April 22, 2026.
201. Centers for Disease Control and Prevention. Update: interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated with pet rodents. MMWR. 2005;54(Dispatch):1-3.
202. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235-2249.
203. Centers for Disease Control and Prevention. Clinical Overview of Variant Creutzfeldt-Jakob Disease. Available at https://www.cdc.gov/variant-creutzfeldt-jakob/hcp/clinical-overview/index.html. Last accessed April 22, 2026.
204. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Biologics Evaluation and Research. Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components: Guidance for Industry. Available at https://www.fda.gov/media/124156/download. Last accessed April 22, 2026.
205. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis. 2001;7(1):6-16.
206. Takemura K, Kahdre M, Joseph D, Yousef A, Sreevatsan S. An overview of transmissible spongiform encephalopathies. Anim Health Res Rev. 2004;5(2):103-124.
207. Centers for Disease Control and Prevention. Bovine Spongiform Encephalopathy (BSE). Available at https://www.cdc.gov/mad-cow/php/animal-health. Last accessed April 22, 2026.
208. George LW. Diseases of the nervous system. In: Smith BP (ed). Large Animal Internal Medicine. 5th ed. St. Louis, MO: Mosby-Year Book, Inc.; 2014.
209. Collinge J. Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet. 1997;6(10):1699-1705.
210. Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: epidemiological studies on the origin. Veterinary Record. 1991;128:199-203.
211. Detwilder LA. Animal Transmissible Spongiform Encephalopathies (TSEs) and Their Impact on Animal and Human Health Worldwide. Yulee, FL: Proceedings of the American Association of Zoo Veterinarians; 1998.
212. Centers for Disease Control and Prevention. Investigation of progressive inflammatory neuropathy among swine slaughterhouse workers—Minnesota, 2007–2008. MMWR. 2008;57(5):1-3.
213. Lachance DH. Outbreak of immune polyradiculoneuropathy in workers exposed to porcine neural tissue. Abstract LBS.001. Academy of Neurology 60th Annual Meeting. Presented April 16, 2008.
214. Thomas FP. Variant Cruetzfeldt-Jakob Disease and Bovine Spongiform Encephalopathy. Available at https://emedicine.medscape.com/article/1169688-overview. Last accessed April 22, 2026.
215. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. Am J Neuroradiol. 2003;24(8):1560-1569.
216. Federal Register. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. Available at https://www.federalregister.gov/documents/2016/01/14/2016-00536/revised-preventive-measures-to-reduce-the-possible-risk-of-transmission-of-creutzfeldt-jakob-disease. Last accessed April 22, 2026.
217. Amaral L, Kristiansen JE. Phenothiazines: potential management of Creutzfeldt-Jakob disease and its variant. Int J Antimicrob Agents. 2001;18(5):411-417.
218. Centers for Disease Control and Prevention. About Toxoplasmosis. Available at https://www.cdc.gov/toxoplasmosis/about/index.html. Last accessed April 22, 2026.
219. Foreyt WJ (ed). Veterinary Parasitology: Reference Manual. 5th ed. Ames, IA: Blackwell Publishing Professional; 2001.
220. Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010;26(4):190-196.
222. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829-1833.
223. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf. Last accessed April 22, 2026.
224. Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf. Last accessed April 22, 2026.
225. Centers for Disease Control and Prevention. About Giardia Infection. Available at https://www.cdc.gov/giardia/about. Last accessed April 22, 2026.
228. Sieloff EM. Giardiasis. Available at https://emedicine.medscape.com/article/176718-overview. Last accessed April 22, 2026.
229. World Health Organization. Malaria. Available at https://www.who.int/en/news-room/fact-sheets/detail/malaria. Last accessed April 22, 2026.
230. Centers for Disease Control and Prevention. Malaria's Impact Worldwide. Available at https://www.cdc.gov/malaria/php/impact. Last accessed April 22, 2026.
231. Centers for Disease Control and Prevention. [Archived Content]. Malaria. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/globalhealth/newsroom/topics/malaria/index.html. Last accessed April 22, 2026.
232. Centers for Disease Control and Prevention. How Malaria Spreads. Available at https://www.cdc.gov/malaria/causes/index.html. Last accessed April 22, 2026.
233. Centers for Disease Control and Prevention. Clinical Features of Malaria. Available at https://www.cdc.gov/malaria/hcp/clinical-features. Last accessed April 22, 2026.
234. World Health Organization. WHO Guidelines for Malaria. Available at https://www.mmv.org/sites/default/files/content/document/WHO-UCN-GMP-2023.01-eng.pdf. Last accessed April 22, 2026.
235. Centers for Disease Control and Prevention. Malaria: Evaluation and Diagnosis. Available at https://www.cdc.gov/malaria/hcp/clinical-guidance/evaluation-diagnosis.html. Last accessed April 22, 2026.
236. van den Hoogen LL, Bareng P, Alves J, et al. Comparison of commercial ELISA kits to confirm the absence of transmission in malaria elimination settings. Front Public Health. 2020;8:480.
237. Centers for Disease Control and Prevention. Clinical Guidance: Malaria Diagnosis and Treatment in the U.S. Available at https://www.cdc.gov/malaria/hcp/clinical-guidance. Last accessed April 22, 2026.
238. Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis. 2010;16(4):672-674.
240. Cennimo DJ. Anthrax. Available at https://emedicine.medscape.com/article/212127-overview. Last accessed April 22, 2026.
241. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287(17):2236-2252.
242. Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR. 2019;68(4):1-14.
243. Heninger SJ, Anderson CA, Beltz G, Onderdonk AB. Decontamination of Bacillus anthracis spores: evaluation of various disinfectants. Appl Biosaf. 2009;14(1):7-10.
244. Centers for Disease Control and Prevention. About Anthrax. Available at https://www.cdc.gov/anthrax/about/. Last accessed April 22, 2026.
245. Shadomy SV, Traxler RM, Marston CK. Infectious diseases related to travel: anthrax. In: CDC's Health Information for International Travel: 2016 (Yellow Book). New York, NY: Oxford University Press; 2015.
246. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2).
247. Withers MR (ed). Medical Management of Biological Casualties Handbook. 8th ed. Fort Detrick, MD: US Army Medical Research Institute of Infectious Diseases; 2014.
248. Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR. 2019;68(4):1-14.
249. Jang KH, Nam S-J, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete. Angew Chem Int Ed Engl. 2013;52(30):7822-7824.
250. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis. 2008;14(4).
251. U.S. Food and Drug Administration. [Archived Content]. FDA Approves Treatment for Inhalation Anthrax. Available at https://wayback.archive-it.org/7993/20170405005211/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm. Last accessed April 22, 2026.
252. U.S. Food and Drug Administration. Vibrio vulnificus Health Education Kit – FDA Letter to Health Educators. Available at https://www.fda.gov/food/buy-store-serve-safe-food/vibrio-vulnificus-health-education-kit-fda-letter-health-educators. Last accessed April 22, 2026.
253. World Health Organization. Cholera. Available at https://www.who.int/health-topics/cholera#tab=tab_1. Last accessed April 22, 2026.
254. Centers for Disease Control and Prevention. Treating Cholera. Available at https://www.cdc.gov/cholera/treatment/index.html. Last accessed April 22, 2026.
255. Infection Control Today. FDA Approves Vaccine to Prevent Cholera in Travelers. Available at https://www.infectioncontroltoday.com/view/fda-approves-vaccine-prevent-cholera-travelers. Last accessed April 22, 2026.
256. Bennett WN. Botulism. Available at https://emedicine.medscape.com/article/213311-overview. Last accessed April 22, 2026.
257. World Health Organization. Botulism. Available at https://www.who.int/news-room/fact-sheets/detail/botulism#. Last accessed April 22, 2026.
258. McCarty CL, Angelo K, Beer KD, et al. Large outbreak of botulism associated with a church potluck meal—Ohio, 2015. MMWR. 2015;64(29):802-803.
259. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA. 1997;278(5):433-435.
260. Centers for Disease Control and Prevention. About Botulism. Available at https://www.cdc.gov/botulism/about/index.html. Last accessed April 22, 2026.
261. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR. 2010;59(10):299.
262. California Department of Public Health. Infant Botulism Treatment and Prevention Program. Available at https://www.cdph.ca.gov/Programs/cls/idld/ibtpp/Pages/International-Inquiries.aspx. Last accessed April 22, 2026.
263. Centers for Disease Control and Prevention. Clinical Overview of Botulism: Treatment. Available at https://www.cdc.gov/botulism/hcp/clinical-overview/index.html#cdc_clinical_overview_treat_pat-treatment-and-recovery. Last accessed April 22, 2026.
264. Centers for Disease Control and Prevention. Clinical Overview of Infant Botulism. Available at https://www.cdc.gov/botulism/hcp/clinical-overview/infant-botulism.html. Last accessed April 22, 2026.
265. Centers for Disease Control and Prevention. Botulism in the United States, 1899–1996: Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Available at https://stacks.cdc.gov/view/cdc/6673. Last accessed April 22, 2026.
266. World Health Organization. Salmonella (Non-Typhoidal). Available at https://www.who.int/en/news-room/fact-sheets/detail/salmonella-(non-typhoidal). Last accessed April 22, 2026.
267. Centers for Disease Control and Prevention. Clinical Overview of Salmonellosis. Available at https://www.cdc.gov/salmonella/hcp/clinical-overview/. Last accessed April 22, 2026.
268. Centers for Disease Control and Prevention. Healthy Pets, Healthy People: Diseases that can Spread Between Animals and People: Salmonellosis (Salmonella Infection). Available at https://www.cdc.gov/healthy-pets/. Last accessed April 22, 2026.
269. Centers for Disease Control and Prevention. About Salmonella Infection. Available at https://www.cdc.gov/salmonella/about/. Last accessed April 22, 2026.
270. Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev. 2012;11:CD001167.
271. Cody SH, Abbott SL, Marfin AA, et al. Two outbreaks of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. 1999;281(19):1805-1810.
272. Bouza E, Sánchez-Carrillo C, Hernangómez S, González MJ. Laboratory-acquired brucellosis: a Spanish national survey. J Hosp Infect. Sep 2005;61(1):80-83.
273. U.S. Department of Agriculture. Brucellosis and Yellowstone Bison. Available at https://www.aphis.usda.gov/media/document/293/file. Last accessed April 22, 2026.
274. Gerberding JL, Romero JM, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 34-2008: a 58-year-old woman with neck pain and fever. N Engl J Med. 2008;359(18):1942-1949.
275. Centers for Disease Control and Prevention. About Brucellosis. Available at https://www.cdc.gov/brucellosis/about/index.html. Last accessed April 22, 2026.
276. Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases. Brucellosis Reference Guide: Exposures, Testing, and Prevention. Available at https://www.cdc.gov/brucellosis/media/pdfs/2025/02/brucellosi-reference-guide.pdf. Last accessed April 22, 2026.
277. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;10:CD007179.
279. Centers for Disease Control and Prevention. Laboratory Identification of Parasitic Diseases of Public Health Concern: Trichinellosis. Available at https://www.cdc.gov/dpdx/trichinellosis/index.html. Last accessed April 22, 2026.
280. Centers for Disease Control and Prevention. Clinical Care of Trichinellosis. Available at https://www.cdc.gov/trichinellosis/hcp/clinical-care/index.html. Last accessed April 22, 2026.
281. Centers for Disease Control and Prevention About Dog or Cat Tapeworm Infection. Available at https://www.cdc.gov/dipylidium/about/. Last accessed April 22, 2026.
282. Centers for Disease Control and Prevention. Laboratory Identification of Parasitic Diseases of Public Health Concern: Dipylidium caninum. Available at https://www.cdc.gov/dpdx/dipylidium/index.html. Last accessed April 22, 2026.
283. Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2010;(1):CD000215.
284. Centers for Disease Control and Prevention. About Anisakiasis. Available at https://www.cdc.gov/anisakiasis/about. Last accessed April 22, 2026.
286. Kita R, Hashida H, Uryuhara K, Kaihara S. Hepatic anisakiasis mimicking metastatic liver tumour. Int J Surg Case Rep. 2019;60:209-212.
1. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Arthritis Care Res (Hoboken). 2021;73(1):1-9. Available at https://www.idsociety.org/practice-guideline/lyme-disease. Last accessed April 28, 2026.
2. American College of Radiology. ACR Appropriateness Criteria: Ataxia. Reston, VA: American College of Radiology; 2023. Available at https://acsearch.acr.org/docs/69477/Narrative. Last accessed April 28, 2026.
3. Maldonado YA, Read JS, Committee on Infectious Diseases. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics. 2017;139(2). Available at https://publications.aap.org/pediatrics/article/139/2/e20163860/59988/Diagnosis-Treatment-and-Prevention-of-Congenital. Last accessed April 28, 2026.
4. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guidelines: Acute Diarrhea in Adults and Children: A Global Perspective. Milwaukee, WI: World Gastroenterology Organisation; 2012. Available at https://www.worldgastroenterology.org/guidelines/global-guidelines/acute-diarrhea/acute-diarrhea-english. Last accessed April 28, 2026.
Mention of commercial products does not indicate endorsement.